62718-28-9

Basic information

• Product Name: 1-METHYLPIPERIDINE-4-CARBOXAMIDE
• Synonyms: N-METHYLPIPERIDINE-4-CARBOXAMIDE;1-METHYLPIPERIDINE-4-CARBOXAMIDE;4-Piperidinecarboxamide,1-methyl-(9CI);1-Methyl-4-PiperidinecarboxaMide;1-methylisonipecotamide
• CAS NO: 62718-28-9
• Molecular Formula: C₇H₁₄N₂O
• Molecular Weight: 142.2
• Product Categories: AMIDE;Pyrans, Piperidines &Piperazines;Pyrans, Piperidines & Piperazines
• Mol File: 62718-28-9.mol

Chemical Properties

• Boiling Point: 286.1°C at 760 mmHg
• Flash Point: 126.8°C
• Appearance: /
• Density: 1.046g/cm³
• Vapor Pressure: 0.0027mmHg at 25°C
• Refractive Index: 1.492
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 1-METHYLPIPERIDINE-4-CARBOXAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-METHYLPIPERIDINE-4-CARBOXAMIDE(62718-28-9)
• EPA Substance Registry System: 1-METHYLPIPERIDINE-4-CARBOXAMIDE(62718-28-9)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 62718-28-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-METHYLPIPERIDINE-4-CARBOXAMIDE is used as a building block for the synthesis of pharmaceuticals and various organic compounds. Its unique chemical structure allows it to be incorporated into the development of new drugs and medications.
Used in Agrochemical Industry:
1-METHYLPIPERIDINE-4-CARBOXAMIDE is used as an intermediate in the production of agrochemicals, such as pesticides and herbicides. Its versatility in chemical reactions enables the creation of effective and targeted agricultural products.
Used as a Precursor in Drug Manufacturing:
1-METHYLPIPERIDINE-4-CARBOXAMIDE is used as a precursor in the manufacturing of drugs such as anesthetics and analgesics. Its presence in the synthesis process contributes to the development of medications that provide pain relief and anesthesia for various medical procedures.

InChI:InChI=1/C7H14N2O/c1-9-4-2-6(3-5-9)7(8)10/h6H,2-5H2,1H3,(H2,8,10)

Upstream product

• 1690-75-1 1-methyl-piperidine-4-carboxylic acid methyl ester 
• 7630-02-6 4-(methoxycarbonyl)-1-methylpyridinium iodide 
• 39546-32-2 4-carboxamidopiperidine 
• 124-38-9 carbon dioxide 
• 1453-82-3 isonicotinamide 
• 2459-09-8 4-pyridinecarboxylic acid, methyl ester 
• 74-88-4 methyl iodide 
• 50-00-0 formaldehyd 

Downstream Products

• 26458-78-6 4-cyanoquinuclidine 
• 92040-00-1 (1-methylpiperidin-4-yl)(phenyl)methanone 
• 20691-91-2 1-(1-methylpiperidin-4-yl)ethanone 
• 65345-83-7 4-cyano-1-methyl-quinuclidinium; iodide 
• 112864-70-7 4-cyano-1-methyl-quinuclidinium; chloride 
• 55022-88-3 1-azabicyclo[2.2.2]octane-4-carboxylic acid 
• 88654-17-5 1-methylpiperidine-4-carbothioamide 
• 1027041-17-3 4-[2-(1,4-dimethyl-piperidin-4-yl)-thiazol-4-yl]-benzoic acid 
• 7149-42-0 1-(1-methylpiperidin-4-yl)methanamine 
• 20691-92-3 1-methylpiperidine-4-carbonitrile 
• 41838-46-4 4-Amino-1-methylpiperidine 

Relevant articles and documents

Electrochemical Reductive N-Methylation with CO2Enabled by a Molecular Catalyst

The development of benign methylation reactions utilizing CO2 as a one-carbon building block would enable a more sustainable chemical industry. Electrochemical CO2 reduction has been extensively studied, but its application for reductive methylation reactions remains out of the scope of current electrocatalysis. Here, we report the first electrochemical reductive N-methylation reaction with CO2 and demonstrate its compatibility with amines, hydroxylamines, and hydrazine. Catalyzed by cobalt phthalocyanine molecules supported on carbon nanotubes, the N-methylation reaction proceeds in aqueous media via the chemical condensation of an electrophilic carbon intermediate, proposed to be adsorbed or near-electrode formaldehyde formed from the four-electron reduction of CO2, with nucleophilic nitrogenous reactants and subsequent reduction. By comparing various amines, we discover that the nucleophilicity of the amine reactant is a descriptor for the C-N coupling efficacy. We extend the scope of the reaction to be compatible with cheap and abundant nitro-compounds by developing a cascade reduction process in which CO2 and nitro-compounds are reduced concurrently to yield N-methylamines with high monomethylation selectivity via the overall transfer of 12 electrons and 12 protons.

Design and synthesis of tri-ring P3 benzamide-containing aminonitriles as potent, selective, orally effective inhibitors of cathepsin K

We have prepared a series of achiral aminoacetonitriles, bearing tri-ring benzamide moieties and an aminocyclohexanecarboxylate residue at P2. This combination of binding elements resulted in sub-250 pM, reversible, selective, and orally bioavailable cathepsin K inhibitors. Lead compounds displayed single digit nanomolar inhibition in vitro (of rabbit osteoclast-mediated degradation of bovine bone). The best compound in this series, 39n (CRA-013783/L-006235), was orally bioavailable in rats, with a terminal half-life of over 3 h. 39n was dosed orally in ovariectomized rhesus monkeys once per day for 7 days. Collagen breakdown products were reduced by up to 76% dose-dependently. Plasma concentrations of 39n above the bone resorption IC50 after 24 h indicated a correlation between functional cellular and in vivo assays. Inhibition of collagen breakdown by cathepsin K inhibitors suggests this mechanism of action may be useful in osteoporosis and other indications involving bone resorption.

PYRAZOLOPYRIMIDINES AS CYCLIN-DEPENDENT KINASE INHIBITORS

In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.

Discovery of 5-[5-fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2, 4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase

To improve the antitumor properties and optimize the pharmaceutical properties including solubility and protein binding of indolin-2-ones, a number of different basic and weakly basic analogues were designed and synthesized. 5-[5-Fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2, 4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide (12b or SU11248) has been found to show the best overall profile in terms of potency for the VEGF-R2 and PDGF-Rβ tyrosine kinase at biochemical and cellular levels, solubility, protein binding, and bioavailability. 12b is currently in phase I clinical trials for the treatment of cancers.